Cerebrospinal fluid biomarkers for diagnosis of Parkinson’s disease: a systematic review and network meta-analysis
Objective: In this study, we intended to use network meta-analysis to compare the diagnostic performances of different CSF biomarkers in the diagnosis and differential diagnosis…Recruiting for Parkinson’s disease risk: Successful engagement tactics to screen for hyposmia in undiagnosed individuals
Objective: Describe recruitment tactics for engaging community in Parkinson’s disease remote risk screening Background: Early clinical markers of PD are critical to identifying biomarker signatures…Informing people with Parkinson’s disease of their gene variant status: PD GENEration, a North American observational and registry study
Objective: To describe genetic testing results of major genes for Parkinson’s disease (PD) in a North American cohort as part of PD GENEration Background: Although…Dopamine depletion of striatal subregions and motor dysfunction in prodromal and clinical Parkinson’s disease
Objective: This aim of this study was to investigate how dopamine depletion of different striatal subregions contributes to motor symptoms in patients with prodromal and…Design of a Phase 2 Study of Suvecaltamide in Moderate to Severe Parkinson’s Disease Tremor
Objective: Describe the design of a phase 2 study (NCT05642442) of a once-daily, extended-release formulation of suvecaltamide to treat moderate to severe Parkinson’s disease tremor…Publication rates and characteristics of clinical trials in deep brain and responsive neurostimulation
Objective: We examine DBS and RNS trials from 1997-2022, chart their characteristics, and examine rates and predictors of results reporting. Background: Prompt dissemination of clinical…Harmonizing genetic testing for early-onset Parkinson’s disease: results of the PARKNET multicentric study
Objective: To harmonize the interpretation of genetic testing in Parkinson's disease (PD) across the PARKNET network, as well as to provide a comprehensive assessment of…Open-label Extension Study of Long-term Safety and Tolerability of Foslevodopa/Foscarbidopa for Treatment of Advanced Parkinson’s Disease
Objective: To evaluate long-term safety/tolerability of foslevodopa/foscarbidopa (LDP/CDP) in patients with advanced Parkinson’s disease (aPD) in a phase 3 open-label extension (OLE) study. Background: LDP/CDP…Understanding neuropsychological features of dopa responsive dystonia in children
Objective: To describe the neuropsychological features in five siblings with dopa responsive dystonia (DRD) due to autosomal dominant GCH1 related disease (AD GCH1). Background: Although…Spontaneous intracranial hypotension presenting with progressive cerebellar ataxia and myelopathy
Objective: To highlight an infrequent, treatable cause of ataxia and myelopathy. Background: Spontaneous intracranial hypotension (SIH) typically presents with postural headache. Occasionally, MRI may show some…
- « Previous Page
- 1
- …
- 156
- 157
- 158
- 159
- 160
- …
- 186
- Next Page »